Active surveillance of intermediate-risk prostate cancer associated with decreased survival
An analysis of data on 945 patients with prostate cancer that was managed with active surveillance showed differences in outcomes depending on whether the patient was low- or intermediate-risk at diagnosis. Compared to patients with low-risk disease, those with intermediate-risk cancer (PSA >10 ng/mL or Gleason score 7 or clinical stage T2b/2c) had a nearly fourfold higher chance of dying from prostate cancer within 15 years. The study was presented at the 2015 Genitourinary Cancers Symposium, in Orlando, Florida.
"For low-risk patients with prostate cancer managed with active surveillance, the risk of dying of prostate cancer is low, validating this approach for this group of patients. More research, however, is needed to better characterize those intermediate-risk patients who can safely be monitored on a surveillance program," said D. Andrew Loblaw, MD, a radiation oncologist at Sunnybrook Health Sciences Centre in Toronto, Canada.
Active surveillance is a globally recognized standard approach for patients with low-risk prostate cancer and select intermediate-risk patients with prostate cancer. Cancer Care Ontario recently released guidelines recommending active surveillance as the preferred approach for low-risk patients. Patients on active surveillance undergo physical examinations, digital rectal examinations, PSA measurements, and repeat tumor biopsies.
According to the authors, this is the first study to examine long-term outcomes of patients with low- vs. intermediate-risk prostate cancer managed on active surveillance.
The researchers analyzed prospectively collected data on 945 patients (237 with intermediate-, 708 with low-risk cancer) who were on active surveillance at Sunnybrook Health Sciences Centre in Canada between 1995 and 2013. Patients whose disease worsened during surveillance were offered treatment (radiation or surgery). In the intermediate risk group, 86 patients received treatment.
The 10-year and 15-year overall survival rates were 68.4% and 50.3% for intermediate-risk patients compared with 83.6% and 68.8% for low-risk patients. The lower survival rate for intermediate-risk patients who were offered active surveillance suggests that these patients had lower life expectancy. Patients with intermediate-risk disease had a 3.75 times higher chance of dying of prostate cancer compared to patients with low-risk disease (11.5% vs. 3.7%, respectively, at 15 years).